Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hodgkin Disease × entinostat × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Melanoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Lymphoma 1 Lung Neoplasms 1 Hodgkin Disease 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 106 fludarabine phosphate 57 Etoposide 57 Mycophenolic Acid 53 Peripheral Blood Stem Cell Transplantation 48 Tacrolimus 46 Melphalan 44 Filgrastim 42 Busulfan 42 Whole-Body Irradiation 41 Radiotherapy 41 Doxorubicin 41 fludarabine 35 Brentuximab Vedotin 33 Vinblastine 32 Cyclosporine 31 Granulocyte Colony-Stimulating Factor 29 Gemcitabine 27 Rituximab 25 Antilymphocyte Serum 25 Methotrexate 24 Dacarbazine 24 Bleomycin 23 Prednisone 21 Vincristine 20 Carmustine 20 Nivolumab 19 pembrolizumab 18 Cytarabine 18 thymoglobulin 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00866333 2019-10-22

ENGAGE-501

Syndax Pharmaceuticals

Phase 2 Terminated

49 enrolled 12 charts

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡